Latest Content

Newron Pharmaceuticals launches a pivotal study on evenamide, targeting treatment-resistant schizophrenia to improve patient outcomes and address unmet needs.

Psychiatric Times celebrates 40 years of advancing mental health care, offering insights, news, and community for psychiatric professionals. Join us in 2026!

Explore innovative solutions to combat burnout in health care, including coaching, psychedelics, and addressing administrative harm for lasting change.

Merck presents promising Phase 1 trial results for MK-2214, a novel Alzheimer treatment, showcasing its potential to slow disease progression.

American psychiatry struggles with understanding psychopathology, emphasizing the need to return to its roots for accurate diagnosis and effective treatment.

What were the top psychiatric hits of 2025?

Psychiatry needs compassionate, culturally competent leaders to address mental health challenges and promote innovative solutions for a healthier future.

Incannex Healthcare's PSX-001 shows promise in treating generalized anxiety disorder, offering innovative, effective solutions beyond traditional therapies.

A critical shortage of IV lorazepam disrupts psychiatric care, particularly for patients with catatonia, highlighting broader pharmaceutical supply chain issues.

New neuroimaging data reveals XPro1595's potential to combat neuroinflammation in early Alzheimer’s disease, offering hope for slowing progression.

Explore the complexities of mental illness, its definitions, and the limitations of current psychiatric diagnosis in understanding true psychopathology.

Bristol Myers Squibb expands patient enrollment in the ADEPT-2 study, exploring Cobenfy's potential for treating Alzheimer disease-related psychosis.

Explore impactful ways to contribute on Giving Tuesday, supporting mental health organizations dedicated to making a difference in psychiatry.